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Abstract
We retrospectively reviewed our experience with 45 kidney
transplant recipients (KTR) that were switched from CNI
to SRL, mainly for chronic allograft dysfunction (CAD)
(41/45). The mean serum creatinine at switch was 2.5 ±
0.8 mg/dl. At 1 year, patient survival was 93%. Death-
censored graft survival was 67% at 1 year and 54% at
2 years. SRL was stopped because of severe side effects
in 15 patients. Among these, eight patients developed ‘de
novo’ high-grade proteinuria. Univariate analysis revealed
that (1) a higher SRL level at 1 month was a predictor of
SRL withdrawal due to severe side effects (P = 0.006), and
(2) predictors of graft failure after SRL conversion were
low SRL loading dose (P = 0.03) and a higher creatinine
level at conversion (P = 0.003).
In conclusion, the therapeutic index of SRL in patients
suffering from CAD is narrow, with high exposure trigger-
ing serious adverse events that may mandate SRL discon-
tinuation, while too low exposure may expose patients to
under-immunosuppression and graft loss.
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Introduction
In some renal transplant recipients, CsA or tacrolimus may
leadtothedevelopmentofCAD.SRL,apotentimmunosup-
pressant with a distinct mechanism of action, may help to
prevent CADprogression[1–9].However, having observed
ahighrateofSRLdiscontinuationinpatientsswitchedfrom
CNI-toSRL-basedimmunosuppression,weretrospectively
analysed our data to further elucidate the safety, efficacy
and side effects of this CAD-attenuating strategy.
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ogy Department, Hopital Erasme, Universit´ e Libre de Bruxelles, 808
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Patients and methods
Our data include 45 renal transplant recipients from two
centres who were switched from CNI- to SRL-based im-
munosuppressant therapy.TheCNIwasabruptlydiscontin-
ued and patients were switched to SRL+steroids. Thirty-
nine patients also received an anti-metabolite (34 received
MMF; 5 received AZA).
Mean age at switch was 42.3 ± 11 (SD) years, and 22
patients (49%) were male. PRA was below 30% in 35/44
patients (79.5%), with a mean number of HLA mismatches
of3.1±1.1.Twenty-fourpercenthadexperiencedprevious
acute rejection before switching to SRL. The median time
fromtransplantationtoconversionwas28.1months(range,
1.4–167 m), and the mean serum creatinine at the time of
switch was 2.5 ± 0.8 mg/dl. There was no deterioration of
renal graft function during the 3-month preceding conver-
sion (serum creatinine at −3 months: 2.46 ± 1.24; at −1
month: 2.46 ± 0.85, P = NS).
For 23 patients, the mean (±SD) SRL loading dose was
12.00 ± 4.41 mg/day for 3 consecutive days, with target
trough levels ranging from 10 to 30 ng/ml. In the remaining
patients, the SRL loading dose was 0.1 mg/kg for 3 days
(mean dose: 5.05 ± 1.68 mg) and the target trough level
was 10 ng/ml. Median follow-up (death, graft loss or last
FU) after SRL conversion was 8.6 months (range, 0.8–
37months).Proteinuriawasevaluatedeitherbythemorning
protein/creatinine ratio or by dipstick analysis.
Results
Patient survival, graft survival and SRL discontinuation
Three deaths occurred after SRL switch. One patient died
from multiple organ failure on Day 58, one from sudden
death on Day 96 and one from cerebral haemorrhage on
Day 156. Actuarial patient survival was 93% at 1 year.
Twelve patients experienced loss of graft function and re-
sumed chronic haemodialysis at a median of 107 days after
SRLconversion(range,23–523).Death-censoredgraftsur-
vival was 67% at 1 year and 54% at 2 years (Figure 1a).
In addition, SRL was discontinued in 15 patients (33.3%)
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Fig. 1. Kaplan–Meier estimate of death-censored graft survival (A) and of patients remaining on sirolimus therapy (B) during 2 years after conversion.
Survival estimates are shown with 95% confidence bands (dotted lines). The population at risk at different time points during follow-up is indicated on
the plot.
because of the occurrence of severe side effects (some
patients developed more than one side effect): resistant
anaemia, N = 1; multiple abdominal abscesses following
acute pancreatitis, N = 1; hepatitis, N = 1; peritransplant
abscess, N = 1; delayed wound healing, N = 1; stroke,
N = 1; infra-therapeutic SRL levels leading to AR, N = 1;
raised Screat >25%, N = 1; severe acneiform cutaneous
lesions, N = 2; severe hyperlipaemia, N = 2; and de novo
high-grade proteinuria, N = 8 (17.7%). In summary, SRL
was stopped in 30/45 (66.6%) patients after conversion (3
deaths, 12 graft loss and 15 discontinuation for side ef-
fects). The actuarial proportion of patients remaining on
SRL therapy over time was 33.6% at 1 year and 26.9% at 2
years after conversion (Figure 1b).
Univariate analysis revealed that SRL levels were
higher at 1 month when the 15 AE-experiencing, SRL-
discontinuing patients were compared with the 30 SRL-
continuing patients (19.4 ± 10 ng/ml versus 11.7 ±
7.8 ng/ml, respectively, P = 0.006).
De novo heavy proteinuria
The mean proteinuria of the whole cohort was 1.0 g/day
at conversion, 1.7 g/day at 1 month (P = 0.008) and
1.9g/dayat3months(P<0.0001).Eightoutof45patients
(18%) developed heavy proteinuria (mean 4.4 g/day, range,
2.5–9.8), which was detected at a median of 9.5 days after
conversion (range, 5–127). Their baseline proteinuria was
1.24 ± 1.16 g/day. Proteinuria returned to pre-switch levels
after SRL discontinuation in 7/8 patients.
Graft function and risk factors for graft loss after SRL
switch
Serum creatinine levels ofthe cohort areshowninFigure 2.
For the overall cohort, serum creatinine levels were stable
during the 3 months before conversion, but increased sig-
nificantly thereafter. When the subgroup of patients who
did not return to dialysis was analysed separately, conver-
sion to sirolimus had no detectable effect on graft function
(mean Pcreat: 2.3 ± 0.7 at conversion versus 2.2 ± 0.8
at final analysis; P = NS; Figure 2). Univariate analysis
comparing the 12 patients who lost their graft with the
33 patients who retained a functioning graft revealed that
a lower SRL loading dose (5.2 mg/day versus 9.8 mg/day,
P = 0.03) and higher serum creatinine at the time of switch
(3.10 mg/dl versus 2.27 mg/dl, P = 0.003) were significant
risk factors for subsequent graft loss. Proteinuria at switch
was higher in patients who went on to lose their graft but
this did not reach statistical significance (1.46 g/day versus
0.84 g/day, P = 0.29).
Discussion
Wemustfirstacknowledgethatthethreeobviousshortcom-
ings to our study are that it is retrospective, it has no control
group and it involves difficult-to-manage CAD patients.
Notwithstanding, a high incidence of severe side effects
mandating SRL discontinuation was observed in one-third
of the patients and was typical of those seen with mTOR
inhibitors.
In our cohort, we could identify that high SRL trough
levels at 1 month after the switch was a significant risk
factor for severe side effects. In our early experience, we
targeted SRL trough levels between 20 and 30 ng/ml, as
recommended inthe twoPhase IItrialswhere de novo KTR
received CNI-free, SRL-based therapy [10,11]. Nowadays,
lower trough levels, such as 8–15 ng/ml, are targeted, with
less toxicity [12].
We found no improvement of renal function after the
switch to sirolimus. This contrasts with a recent meta-
analysis, where patients with CAD switched from CNI
to SRL experienced a significant 6 ml/min improvement
in creatinine clearance [13]. This difference is probably
due to the patients in the meta-analysis having better pre-
served renal function at the time of switch (CrCl was
47 ml/min, versus 35 ml/min in our study). Indeed, results
from the recent ‘Convert’ study, where patients with creati-
nineclearance<40ml/minexperiencedahighincidenceof
adverse events with no corresponding renal function bene-
fits [14], have suggested that conversion to SRL followingSirolimus for chronic renal allograft dysfunction 3729
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Fig. 2. Serum creatinine over time. Data were available for 41, 44, 45, 44 and 42 patients at −3 months, −1 month, at switch, +1 month and last
follow-up, respectively. Hypothesis testing by repeated measures ANOVA, between day of switch and day of last follow-up. The median days of
follow-up for patients who lost graft function and those who retained a functioning graft were 107 and 376, respectively.
CAD should only be undertaken in patients with creati-
nine <2.5 mg/dl [15]. Similarly, Wali et al. concluded that
conversion from tacrolimus to SRL is ineffective when the
mean creatinine level reaches 3.8 mg/dl [16]. Our findings
substantiate these observations.
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